<DOC>
	<DOCNO>NCT00003781</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase II trial docetaxel treat patient stage IV prostate cancer respond hormone therapy .</brief_summary>
	<brief_title>Docetaxel Treating Patients With Stage IV Prostate Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Evaluate efficacy weekly docetaxel measure disease response , strength duration pain reduction , either decrease analgesic use without increase pain , decrease PSA , patient hormone refractory metastatic prostate cancer . II . Assess efficacy regimen term survival patient population . III . Evaluate effect regimen quality life patient . IV . Determine qualitative quantitative toxicity regimen patient . OUTLINE : Patients receive docetaxel IV 15-30 minute weekly 6 week . Courses repeat every 8 week . Therapy continue absence disease progression unacceptable toxicity . Quality life assess week 1 , 3 , 5 , 7 course , daily pain medication diary maintain treatment . Patients follow 1 month resolution toxicity , every 3 month death . PROJECTED ACCRUAL : A total 25 patient accrue study .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm stage IV hormone refractory adenocarcinoma prostate Symptoms evidence disease progression despite standard hormonal therapy PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 03 Life expectancy : At least 3 month Hematopoietic : WBC least 3000/mm3 Neutrophil count least 1500/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin great upper limit normal ( ULN ) ALT great 2 time ULN ( great 1.5 time ULN alkaline phosphatase great 2.5 time ULN ) Alkaline phosphatase great 4 time ULN ( great 8 time ULN know bone involvement bilirubin ALT normal range ) Renal : Not specify Other : At least 5 year since prior malignancy except nonmelanoma skin cancer No significant medical illness would prevent compliance No hypersensitivity drug formulate polysorbate80 Must able complete write questionnaires diary PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior chemotherapy Endocrine therapy : See Disease Characteristics Radiotherapy : At least 1 month since prior radiotherapy At least 2 month since prior strontium89 Surgery : Not specify Other : At least one month since prior investigational agent</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>adenocarcinoma prostate</keyword>
	<keyword>stage IV prostate cancer</keyword>
	<keyword>recurrent prostate cancer</keyword>
	<keyword>pain</keyword>
</DOC>